NZ502874A - Antihyperlipidemic statin-lp(a) inhibitor combinations - Google Patents
Antihyperlipidemic statin-lp(a) inhibitor combinationsInfo
- Publication number
- NZ502874A NZ502874A NZ502874A NZ50287498A NZ502874A NZ 502874 A NZ502874 A NZ 502874A NZ 502874 A NZ502874 A NZ 502874A NZ 50287498 A NZ50287498 A NZ 50287498A NZ 502874 A NZ502874 A NZ 502874A
- Authority
- NZ
- New Zealand
- Prior art keywords
- pharmaceutically acceptable
- statin
- pharmaceutical composition
- kit
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6943297P | 1997-12-12 | 1997-12-12 | |
PCT/US1998/023480 WO1999030706A1 (fr) | 1997-12-12 | 1998-11-04 | Compositions antilipemiques combinant un inhibiteur de lipoproteine (a) et une statine |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ502874A true NZ502874A (en) | 2004-03-26 |
Family
ID=22088939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ502874A NZ502874A (en) | 1997-12-12 | 1998-11-04 | Antihyperlipidemic statin-lp(a) inhibitor combinations |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1037623A1 (fr) |
JP (1) | JP2003524582A (fr) |
KR (1) | KR20010033017A (fr) |
AU (2) | AU1306099A (fr) |
BR (1) | BR9813539A (fr) |
CA (1) | CA2299397A1 (fr) |
HU (1) | HUP0100349A3 (fr) |
IL (1) | IL134364A0 (fr) |
IS (1) | IS5385A (fr) |
NO (1) | NO20002965L (fr) |
NZ (1) | NZ502874A (fr) |
PL (1) | PL343851A1 (fr) |
WO (1) | WO1999030706A1 (fr) |
ZA (1) | ZA9811349B (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU739020B2 (en) | 1997-01-07 | 2001-10-04 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the reduction of food intake |
EP1076091A1 (fr) * | 1999-08-09 | 2001-02-14 | Universite Catholique De Louvain | Composé ou composition pharmaceutique pour la prévention et/ou le traitement d'ischémie cardiaque, de maladies vasculaires périphériques, de tumeurs et de plaies |
WO2001051078A1 (fr) * | 2000-01-10 | 2001-07-19 | Amylin Pharmaceuticals, Inc. | Utilisation d'exendines et d'agonistes de ces dernieres pour moduler les taux de triglycerides et pour traiter la dyslipidemie |
EP1275388A4 (fr) * | 2000-02-10 | 2003-11-26 | Takeda Chemical Industries Ltd | Inhibiteurs de tnf-alpha |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2016467A1 (fr) * | 1989-06-05 | 1990-12-05 | Martin Eisman | Methode de traitement de l'atherosclerose des vaisseaux peripheriques a l'aide d'un inhibiteur de l'hmg coa reductase et (ou) d'un inhibiteur de la squalene synthetase |
WO1993013801A1 (fr) * | 1992-01-17 | 1993-07-22 | The Procter & Gamble Company | Traitement de l'arteriosclerose |
CA2129732A1 (fr) * | 1992-02-25 | 1993-09-02 | Alain Martin | Compositions cytoprotectrices contenant du pyruvate et des antioxydants |
US5720963A (en) * | 1994-08-26 | 1998-02-24 | Mary Kay Inc. | Barrier disruption treatments for structurally deteriorated skin |
US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
EP0738510A3 (fr) * | 1995-04-20 | 2005-12-21 | L'oreal | Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes |
EP0904082A4 (fr) * | 1996-04-17 | 2001-09-26 | Merck & Co Inc | Therapie d'association destinee a reduire les risques lies a une maladie cardio-vasculaire |
NZ503982A (en) * | 1997-12-12 | 2002-03-28 | Warner Lambert Co | Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus |
-
1998
- 1998-11-04 KR KR1020007006370A patent/KR20010033017A/ko not_active Application Discontinuation
- 1998-11-04 BR BR9813539-2A patent/BR9813539A/pt not_active Application Discontinuation
- 1998-11-04 CA CA002299397A patent/CA2299397A1/fr not_active Abandoned
- 1998-11-04 IL IL13436498A patent/IL134364A0/xx unknown
- 1998-11-04 EP EP98956562A patent/EP1037623A1/fr not_active Ceased
- 1998-11-04 JP JP2000538689A patent/JP2003524582A/ja active Pending
- 1998-11-04 NZ NZ502874A patent/NZ502874A/en unknown
- 1998-11-04 WO PCT/US1998/023480 patent/WO1999030706A1/fr not_active Application Discontinuation
- 1998-11-04 HU HU0100349A patent/HUP0100349A3/hu unknown
- 1998-11-04 AU AU13060/99A patent/AU1306099A/en not_active Abandoned
- 1998-11-04 PL PL98343851A patent/PL343851A1/xx unknown
- 1998-12-10 ZA ZA9811349A patent/ZA9811349B/xx unknown
-
2000
- 2000-02-25 IS IS5385A patent/IS5385A/is unknown
- 2000-06-09 NO NO20002965A patent/NO20002965L/no not_active Application Discontinuation
-
2003
- 2003-08-29 AU AU2003244047A patent/AU2003244047A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HUP0100349A2 (hu) | 2001-07-30 |
HUP0100349A3 (en) | 2002-02-28 |
AU1306099A (en) | 1999-07-05 |
CA2299397A1 (fr) | 1999-06-24 |
PL343851A1 (en) | 2001-09-10 |
ZA9811349B (en) | 1999-06-14 |
NO20002965D0 (no) | 2000-06-09 |
KR20010033017A (ko) | 2001-04-25 |
EP1037623A1 (fr) | 2000-09-27 |
IL134364A0 (en) | 2001-04-30 |
IS5385A (is) | 2000-02-25 |
AU2003244047A1 (en) | 2003-09-25 |
BR9813539A (pt) | 2000-10-10 |
WO1999030706A1 (fr) | 1999-06-24 |
NO20002965L (no) | 2000-06-09 |
JP2003524582A (ja) | 2003-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1491193B1 (fr) | Combinaisons thérapeutiques contenant de l'amlodipine et de l'atorvastatine | |
AP1207A (en) | Combination therapy. | |
EP1045691B1 (fr) | Combinaisons de statine-carboxyalkylether | |
US20070149578A1 (en) | Combination Therapy | |
US8557835B2 (en) | Statin-carboxyalkylether combinations | |
NZ502874A (en) | Antihyperlipidemic statin-lp(a) inhibitor combinations | |
US20020103252A1 (en) | Statin-carboxyalkylether combinations | |
EP1280522B1 (fr) | Combinaison de carboxyalkylethers avec des agents antihypertenseurs et leur utilisation | |
US20040092574A1 (en) | Statin-Lp(a) inhibitor combinations | |
EP1481962A1 (fr) | Nouveau carboxyéthylether reduisant la cholesterolémie | |
MXPA00002105A (en) | Antihyperlipidemic statin-lp(a) inhibitor combinations | |
US20030225123A1 (en) | Antihypertensive agents and use | |
MXPA00002104A (en) | Carton with panel locking means | |
MXPA00002085A (en) | Combination therapy comprising amlodipine and a statin compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RENW | Renewal (renewal fees accepted) | ||
PSEA | Patent sealed |